Hizentra CIDP denied as not medically necessary by Humana?

Humana's specific coverage criteria for hizentra cidp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny Hizentra for CIDP as Not Medically Necessary

Humana's medical-necessity review for Hizentra in chronic inflammatory demyelinating polyneuropathy (CIDP) evaluates whether the member's clinical presentation meets the criteria outlined in Humana's coverage policy for immune globulin therapy. Denials typically occur when the submitted documentation does not clearly establish: (a) a confirmed CIDP diagnosis supported by objective testing, (b) adequate documentation of prior therapy and response, (c) current disease activity or functional impairment, or (d) that the prescribed regimen aligns with the criteria in Humana's policy and the FDA-approved prescribing label.

Because CIDP is a variable, relapsing-remitting condition, medical-necessity denials often stem from incomplete documentation rather than from a genuinely non-qualifying clinical picture. A thorough appeal that maps each criterion to a specific chart fact resolves the majority of these cases.

## Federal Appeal Rights

• ACA §2719 / external review: After exhausting Humana's internal appeal process, you may request independent external review. The standard window is approximately four months from the initial denial; your denial letter will state the exact deadline. Expedited external review (typically 72 hours) is available when standard review would seriously jeopardize your health or ability to function.
• ERISA §503: For self-funded employer plans, Humana must provide the specific medical-necessity criteria applied, the clinical basis for the denial, and a full-and-fair opportunity to appeal.

## What to Gather

1. Diagnosis confirmation — neurology notes documenting the CIDP diagnosis, including objective testing (nerve conduction studies, EMG, or CSF analysis as applicable) and the clinical course over time. 2. Functional impairment documentation — physician notes describing current motor, sensory, or functional deficits and their impact on daily activities. 3. Prior treatment history — a dated, outcome-documented list of prior CIDP therapies, explaining why each was discontinued or inadequate. 4. Prescriber medical-necessity letter — a comprehensive letter from the treating neurologist explaining why Hizentra is the appropriate therapy for this patient at this stage of disease, referencing applicable guideline organizations (e.g., the American Academy of Neurology) without citing specific numeric thresholds. 5. Humana's coverage policy — obtain the current policy for immune globulin/CIDP and address each stated criterion explicitly in the appeal.

## Criteria-Mapping Structure

| Humana Medical-Necessity Criterion | Chart Evidence Satisfying It | |---|---| | Each stated requirement | Exact date, note, test, or result from the record |